DENGUE VACCINES MARKET ANALYSIS
Dengue fever, also known as breakbone fever, is a mosquito-borne viral infection causing a severe flu-like illness. The condition can lead to a potentially lethal complication called severe dengue. Dengue vaccine is a vaccine used to prevent dengue fever in humans.
Dengue vaccine is only recommended in those who have previously had dengue fever. It is given as three injections over a year.
Statistics:
The global dengue vaccine market is estimated to account for US$ 1,262.0 Mn in terms of value by the end of 2027.
Market Trends/Key Takeaways
Major players in the market are launching their products in emerging markets, instead of opting for developed markets. For instance, Sanofi first introduced Dengvaxia in Philippines.
Countries with high incidence of dengue are introducing mass vaccination programs. For instance, in August 2019, the government of Philippines announced its plan for mass vaccination for dengue after dengue outbreak in the Philippines.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients